文献速递血栓与止血

康赛珠单抗联合旁路药物或凝血因子对凝血酶生成潜力的体外及离体分析

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
PubMed 文献 · J Thromb Haemost · 2021-05-06

康赛珠单抗(concizumab)用于血友病A/B皮下预防治疗。体外和离体实验显示,康赛珠单抗以浓度依赖方式增加凝血酶峰值,联合rFVIIa、APCC、rFVIII或rFIX后凝血酶峰值进一步升高,效应主要为相加作用,药物相互作用额外效应不超过约25%,无强协同作用。

要点

  • 康赛珠单抗浓度依赖性增加凝血酶峰值。
  • 联合rFVIIa、APCC、rFVIII或rFIX后凝血酶峰值进一步升高。
  • 联合效应主要为相加,药物相互作用额外效应不超过约25%。

核心结论

  • rFVIIa、APCC、rFVIII和rFIX在康赛珠单抗存在下增强血浆凝血酶生成潜力。
  • 康赛珠单抗与上述药物的联合效应主要为相加,无强协同作用。

研究设计与样本

  • 体外研究:混合血友病A血浆加康赛珠单抗单用或联合rFVIIa、APCC或rFVIII;混合血友病B血浆加康赛珠单抗单用或联合rFIX。
  • 离体研究:接受康赛珠单抗预防的血友病A患者血浆中加入rFVIIa、APCC和rFVIII。
  • 凝血酶生成潜力以组织因子启动后测定。

主要发现

  • 康赛珠单抗以浓度依赖方式增加凝血酶峰值。
  • 加入rFVIIa、APCC、rFVIII或rFIX后凝血酶峰值进一步增加。
  • 康赛珠单抗与rFVIIa、APCC、rFVIII或rFIX的效应主要为相加,药物相互作用导致无或最多约25%的额外效应。
  • 康赛珠单抗存在下0.5 IU/ml rFVIII或rFIX的凝血酶峰值有时略高于无康赛珠单抗时1 IU/ml rFVIII或rFIX的峰值,但多数相当。

临床怎么用

  • 联合使用时应调整剂量以平衡安全性担忧并维持必要止血效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The anti-tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis may be treated with bypassing agents (recombinant activated factor VIIa [rFVIIa] and activated prothrombin complex concentrate [APCC]), or with factor VIII (FVIII) or factor IX (FIX). OBJECTIVES: To evaluate the effect of combining concizumab with rFVIIa, APCC, rFVIII, and rFIX on thrombin generation (TG) potential. METHODS: Pooled HA plasma was spiked in vitro with concizumab alone or together with rFVIIa, APCC, or rFVIII. rFVIIa, APCC, and rFVIII were added ex vivo to plasma from HA patients receiving concizumab prophylaxis. Pooled HB plasma was spiked with concizumab alone or together with rFIX. TG potential was measured after initiation with tissue factor. RESULTS: Concizumab increased thrombin peak in a concentration-dependent manner. Adding rFVIIa, APCC, rFVIII, or rFIX caused a further increase in thrombin peak. The effects of concizumab and rFVIIa, APCC, rFVIII, or rFIX were mainly additive, with no or up to maximally ~25% extra effect caused by drug--drug interaction. No strong synergistic effects were observed upon combining concizumab with rFVIIa, APCC, rFVIII, or rFIX. The thrombin peak obtained with 0.5 IU/ml rFVIII or rFIX in the presence of concizumab was on occasion slightly higher, but mostly comparable to the thrombin peak with 1 IU/ml rFVIII or rFIX in the absence of concizumab. CONCLUSION: rFVIIa, APCC, rFVIII, and rFIX enhanced plasma TG potential in the presence of concizumab. Dose levels of concomitant use should be adjusted accordingly to balance potential safety concerns while maintaining the necessary hemostatic effect. Please see the video in the Supplementary Material for an animated summary of the data presented.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kjalke M, Kjelgaard-Hansen M, Andersen S, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021. PMID: 33819375. doi:10.1111/jth.15323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。